- R&D Pipeline
- Season 2 (2021-2030)
| Modality | Indication | Targets | Stage | Company | Project No. | Detail | |
|---|---|---|---|---|---|---|---|
| 1 | Generation of hit/lead compounds to treat multiple sclerosis by targeting formyl peptide receptor | ||||||
| Peptide | Multiple Sclerosis | FPR | Hit | Sungkyunkwan University | HN22C0255 | ||
| 2 | Topical immunotherapeutic agent for atopic dermatitis : FPR2-selective pro-resolving peptide ligand | ||||||
| Peptide | Atopic dermatitis | FPR2 | Phase 1 | Novacell technology Inc. | HN21C1061 | ||